HepBest (Tenofovir Alafenamide) – Next-Generation Hepatitis B Treatment

HepBest (Tenofovir Alafenamide Fumarate / TAF) is a next-generation nucleotide analogue for the treatment of chronic Hepatitis B virus (HBV) infection. TAF delivers antiviral activity at a fraction of the dose of older Tenofovir formulations, with equivalent efficacy and significantly less kidney and bone toxicity.
Why TAF over TDF?
Delivers targeted antiviral activity directly to liver cells
Substantially lower risk of kidney and bone density side effects
Once-daily tablet — simple, convenient regimen
Effective across all major HBV genotypes
Prescription-only antiviral. Regular monitoring of liver function and viral load is essential. Do not discontinue without medical advice — abrupt cessation can cause severe HBV reactivation.